Exploring the mechanism of comorbidity in patients with T1DM and COVID-19: Integrating bioinformatics and Mendelian randomization methods

Tingliang Wang,Yun Zhang,Chunjiao Wu,Zhenxing Huang,Xinghuan Liang,Zuojie Luo
DOI: https://doi.org/10.1097/md.0000000000040128
IF: 1.6
2024-10-30
Medicine
Abstract:Type 1 diabetes mellitus (T1DM), an autoimmune disease characterized by hyperglycemia and insulin dependence, is influenced by a complex interplay of various environmental, microbial, genetic, metabolic, and immune factors. Viral infections, such as coxsackievirus, cytomegalovirus, and enterovirus infections, have been identified as potential triggers for the development of T1DM. Recent studies have focused on the potential connection between T1DM and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suggesting a bidirectional relationship between the 2 conditions. [ 1–3 ] Both diseases seem to promote the other. However, the causal relationship between the 2 diseases has not been verified. Moreover, several studies have shown that the coronavirus disease 2019 (COVID-19) can lead to more complications and higher mortality in T1DM, [ 4–6 ] and T1DM is also associated with an increased risk of serious infections and higher mortality in patients with COVID-19, [ 7 , 8 ] highlighting the complex interplay between the 2 diseases and the burden it places on global healthcare systems. In addition to T1DM, type 2 diabetes mellitus (T2DM) represents the most common form of diabetes. The complex interplay between T2DM and COVID-19 has also attracted extensive research interest. This body of research encompasses bioinformatics analyses, [ 9 , 10 ] Mendelian randomization (MR) studies, [ 11 , 12 ] clinical observational research, and experimental studies. These investigations have elucidated common differentially expressed genes (DEGs) and enriched pathways that link T2DM and COVID-19. Moreover, they have explored the shared pathophysiological mechanisms underlying both diseases, such as immune dysregulation, chronic inflammation, aberrant expression of angiotensin-converting enzyme 2, and dysregulated cytokine expression. [ 13–16 ] Furthermore, the potential therapeutic implications of T2DM pharmacotherapy for COVID-19 have been examined. [ 17 , 18 ] Building upon this research, we posit that there may be also a genetic overlap between T1DM and COVID-19, which could be identified through the analysis of DEGs. This genetic overlap is hypothesized to be associated with a protective or aggravating effect on the concomitant occurrence of both diseases. Specifically, this study aims to analyze the shared DEGs associated with both T1DM and COVID-19 to elucidate the shared pathogenic pathways by employing integrated bioinformatics and enrichment analysis.
medicine, general & internal
What problem does this paper attempt to address?